Compare Stocks: BRNS, BMEA, ACET, and RLYB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.11 +1.6%	$8.32	$6.01 ▼ $17.44	$74.60M	1.6	97,249 shs	85,721 shs
BMEA Biomea Fusion	$1.27 +0.8%	$1.27	$0.87 ▼ $2.99	$91.10M	-0.28	518,141 shs	421,128 shs
BRNS Barinthus Biotherapeutics	$0.56 -6.2%	$0.64	$0.51 ▼ $1.83	$24.47M	-0.39	42,386 shs	21,498 shs
RLYB Rallybio	$16.61 +2.8%	$16.04	$3.20 ▼ $17.57	$85.82M	-0.9	41,414 shs	23,318 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+1.63%	-12.23%	-8.15%	+2.01%	-18.38%
BMEA Biomea Fusion	+0.79%	+5.83%	-3.79%	-19.62%	-17.53%
BRNS Barinthus Biotherapeutics	-6.16%	-6.30%	-10.35%	-19.70%	-58.05%
RLYB Rallybio	+2.78%	+4.14%	+5.59%	+18.39%	+291.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.11 +1.6%	$8.32	$6.01 ▼ $17.44	$74.60M	1.6	97,249 shs	85,721 shs
BMEA Biomea Fusion	$1.27 +0.8%	$1.27	$0.87 ▼ $2.99	$91.10M	-0.28	518,141 shs	421,128 shs
BRNS Barinthus Biotherapeutics	$0.56 -6.2%	$0.64	$0.51 ▼ $1.83	$24.47M	-0.39	42,386 shs	21,498 shs
RLYB Rallybio	$16.61 +2.8%	$16.04	$3.20 ▼ $17.57	$85.82M	-0.9	41,414 shs	23,318 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+1.63%	-12.23%	-8.15%	+2.01%	-18.38%
BMEA Biomea Fusion	+0.79%	+5.83%	-3.79%	-19.62%	-17.53%
BRNS Barinthus Biotherapeutics	-6.16%	-6.30%	-10.35%	-19.70%	-58.05%
RLYB Rallybio	+2.78%	+4.14%	+5.59%	+18.39%	+291.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.75	Moderate Buy	$46.80	477.07% Upside
BMEA Biomea Fusion	2.67	Moderate Buy	$8.20	545.67% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	611.62% Upside
RLYB Rallybio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRNS, BMEA, ACET, and RLYB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/15/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/26/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/11/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	1.53	N/A	N/A	$1.82 per share	0.31
RLYB Rallybio	$860K	102.56	N/A	N/A	$10.98 per share	1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	N/A
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	N/A
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	N/A
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	N/A

Latest BRNS, BMEA, ACET, and RLYB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A
8/6/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A
5/13/2026	Q1 2026	ACET Adicet Bio	-$2.93	-$1.88	+$1.05	-$1.88	N/A	N/A
5/13/2026	Q1 2026	RLYB Rallybio	-$1.20	-$1.46	-$0.26	-$1.46	$0.21 million	$0.21 million
5/11/2026	Q1 2026	BMEA Biomea Fusion	-$0.24	-$0.17	+$0.07	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	$0.04	0.49%	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
BMEA Biomea Fusion	N/A	3.47	3.47
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
RLYB Rallybio	N/A	27.26	27.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
BMEA Biomea Fusion	96.72%
BRNS Barinthus Biotherapeutics	25.20%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
BMEA Biomea Fusion	10.60%
BRNS Barinthus Biotherapeutics	8.50%
RLYB Rallybio	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	90	9.35 million	9.04 million	Optionable
BMEA Biomea Fusion	50	72.30 million	64.64 million	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable

BRNS, BMEA, ACET, and RLYB Headlines

Recent News About These Companies

Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS

August 6, 2026 | marketbeat.com

Rallybio (RLYB) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest

July 27, 2026 | marketbeat.com

Rallybio (NASDAQ:RLYB) Trading 1% Higher - Time to Buy?

July 14, 2026 | marketbeat.com

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

June 2, 2026 | businesswire.com

Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing

June 2, 2026 | thepharmaletter.comT

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

June 1, 2026 | finance.yahoo.com

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

June 1, 2026 | businesswire.com

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

June 1, 2026 | businesswire.com

Rallybio Corporation

May 22, 2026 | edition.cnn.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 Shares

May 21, 2026 | insidertrades.com

Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock

May 16, 2026 | investing.com

Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of Stock

May 16, 2026 | insidertrades.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares

May 14, 2026 | insidertrades.com

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 Shares

May 7, 2026 | insidertrades.com

Rallybio Receives Termination Fee After Candid Deal Collapse

May 4, 2026 | tipranks.com

Rallybio CMO Departs Amid Pending Candid Therapeutics Merger

March 31, 2026 | tipranks.com

Candid lists via Rallybio reverse merger, adds $505m financing

March 5, 2026 | thepharmaletter.comT

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

March 4, 2026 | businesswire.com

Rallybio Corp.

March 3, 2026 | marketwatch.com

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

March 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, BMEA, ACET, and RLYB Company Descriptions

Adicet Bio NASDAQ:ACET

$8.11 +0.13 (+1.63%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$8.09 -0.02 (-0.22%)

As of 07:07 AM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Biomea Fusion NASDAQ:BMEA

$1.27 +0.01 (+0.79%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$1.27 +0.00 (+0.31%)

As of 07:01 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.56 -0.04 (-6.16%)

Closing price 08/10/2026 03:59 PM Eastern

Extended Trading

$0.58 +0.02 (+3.90%)

As of 07:00 AM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Rallybio NASDAQ:RLYB

$16.61 +0.45 (+2.78%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$16.99 +0.38 (+2.29%)

As of 07:00 AM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, BMEA, ACET, and RLYB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, BMEA, ACET, and RLYB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, BMEA, ACET, and RLYB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, BMEA, ACET, and RLYB Company Descriptions

Adicet Bio NASDAQ:ACET

Biomea Fusion NASDAQ:BMEA

Barinthus Biotherapeutics NASDAQ:BRNS

Rallybio NASDAQ:RLYB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, BMEA, ACET, and RLYB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, BMEA, ACET, and RLYB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, BMEA, ACET, and RLYB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, BMEA, ACET, and RLYB Company Descriptions

Adicet Bio NASDAQ:ACET

Biomea Fusion NASDAQ:BMEA

Barinthus Biotherapeutics NASDAQ:BRNS

Rallybio NASDAQ:RLYB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools